Our rapidly growing pipeline
We aim for first-in-class therapeutics. For promising target candidates, we have developed high-throughput screening assays and entered the drug discovery phase. Assets are available for licensing or provide a foundation for R&D partnerships to bring novel therapeutics successfully to the market.
Indivumed Pipeline
Do you want to learn more?
Get in touch if you are interested in details of our current and future pipeline, ongoing development programs, or additional indications. We are happy to discuss a potential collaboration.
Our Pipeline What makes our assets stand out?
Our targets are the result of a patient-centric approach that is truly unique from the very first step. Starting with nonischemic, highly standardized tumor samples from patients all over the world, we create proprietary multi-omics datasets. In our holistic target identification and validation process, we utilize this data as well as the source samples to enhance the probability of successful therapeutic development.
)
“Our R&D approach brings novel insights through our unique starting point. Carefully collected and curated patient samples are excellent representations of the characteristic features of the disease, making the difference in target discovery and lead generation toward innovative and successful therapeutics.”